Company profile
Decision Diagnostics Corp.
OTC: DECN · Healthcare · Medical - Pharmaceuticals
#690 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 11GM —SS 40
v0.1 · 25/100 weight · pillars only
↑ listing tenure, net margin · ↓ disclosure history, filing timeliness
Methodology →Revenue TTM
$2.1M
Rev growth YoY (TTM)
-2.7%
Net income (FY)
-$3.1M
Employees
6
as of 2026-08-29
Market cap
$35.8k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$6.2M$6.2M2012
Net income-$3.1M-$3.1M2012
Operating income-$2.7M-$2.7M2012
Total assets$4.1M$4.1M2012
Equity$851.6k$851.6k2012
Revenue trend
FY2011 – FY2012 · USD
FY11
FY12
FY12
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Decision Diagnostics Corp.’s revenue?
Decision Diagnostics Corp. booked $6.2M in FY2012 revenue, contracting 49% year over year — slower than 81% of Healthcare companies we track, at a -49.7% net margin.
Peers · Healthcare
HTG Molecular Diagnostics, Inc.——Jack Nathan Medical Corp.——Scorpius Holdings, Inc.——bioAffinity Technologies, Inc.32DOracle Healthcare Acquisition Corp.——Bloomios, Inc.——Neighbors
Los Angeles →Key facts
CEOKeith Berman
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersWestlake Village, CA
ExchangeOTC: DECN
Employees6
IPO date2002-02-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.